MX343058B - Proceso para la fabricacion de degarelix y sus intermedios. - Google Patents

Proceso para la fabricacion de degarelix y sus intermedios.

Info

Publication number
MX343058B
MX343058B MX2013004320A MX2013004320A MX343058B MX 343058 B MX343058 B MX 343058B MX 2013004320 A MX2013004320 A MX 2013004320A MX 2013004320 A MX2013004320 A MX 2013004320A MX 343058 B MX343058 B MX 343058B
Authority
MX
Mexico
Prior art keywords
degarelix
amino protecting
protecting group
protecting groups
hydrogen
Prior art date
Application number
MX2013004320A
Other languages
English (en)
Other versions
MX2013004320A (es
Inventor
Jon Holbech Rasmussen
Jens Fomsgaard
Stefan Hansen
Palle Hedengran Rasmussen
Wolfgang Oliver Wachs
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2013004320A publication Critical patent/MX2013004320A/es
Publication of MX343058B publication Critical patent/MX343058B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un proceso de fabricación de la fase líquida (o solución) para preparar el decapéptido Degarelix, su precursor protegido y otros productos intermedios útiles. La invención se refiere además a polipéptidos utilizados en el proceso de fabricación de la fase de solución y a la purificación de Degarelix en sí mismo. Degarelix puede obtenerse condicionando un precursor de Degarelix de acuerdo con la fórmula II: (P1) AA1-AA2 AA3-AA4 (P4) -AA5-AA6 (P6) -AA7-AA8 (P8) -AA9-AA10-NH2 (II) o una sal o solvato de la misma, a un tratamiento con un agente de escisión en un solvente Orgánico, donde P1 es un grupo protector amino; preferentemente acetilo; P4 es hidrógeno o un grupo protector hidroxilo, preferentemente un grupo protector hidroxilo; P6 es hidrógeno o un grupo protector amino; preferentemente un grupo protector amino; y P8 es un grupo protector amino.
MX2013004320A 2010-10-27 2011-10-26 Proceso para la fabricacion de degarelix y sus intermedios. MX343058B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10189032A EP2447276A1 (en) 2010-10-27 2010-10-27 Process for the manufacture of Degarelix and its intermediates
PCT/EP2011/068735 WO2012055905A1 (en) 2010-10-27 2011-10-26 Process for the manufacture of degarelix and its intermediates

Publications (2)

Publication Number Publication Date
MX2013004320A MX2013004320A (es) 2013-12-02
MX343058B true MX343058B (es) 2016-10-24

Family

ID=43531147

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004320A MX343058B (es) 2010-10-27 2011-10-26 Proceso para la fabricacion de degarelix y sus intermedios.

Country Status (26)

Country Link
US (2) US9090656B2 (es)
EP (2) EP2447276A1 (es)
JP (1) JP6007187B2 (es)
KR (1) KR101904808B1 (es)
CN (1) CN103180335B (es)
AU (1) AU2011322618B2 (es)
BR (1) BR112013010360B1 (es)
CA (1) CA2815270A1 (es)
DK (1) DK2632935T3 (es)
ES (1) ES2606753T3 (es)
HR (1) HRP20161315T1 (es)
HU (1) HUE030184T2 (es)
IL (1) IL225687A (es)
JO (1) JO3243B1 (es)
LT (1) LT2632935T (es)
MX (1) MX343058B (es)
NZ (1) NZ609064A (es)
PL (1) PL2632935T3 (es)
PT (1) PT2632935T (es)
RS (1) RS55193B1 (es)
RU (1) RU2602042C2 (es)
SA (1) SA111320880B1 (es)
SI (1) SI2632935T1 (es)
TW (1) TWI515201B (es)
WO (1) WO2012055905A1 (es)
ZA (1) ZA201302670B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
CN105663059A (zh) * 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
RS55457B1 (sr) 2010-10-27 2017-04-28 Ferring Bv Postupak za proizvodnju degareliksa i njegovih intermedijara
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
RU2657444C2 (ru) 2012-06-01 2018-06-13 Ферринг Б.В. Получение дегареликса
CN103992378A (zh) * 2013-11-01 2014-08-20 杭州诺泰制药技术有限公司 一种制备醋酸地加瑞克的方法
CN106589071B (zh) * 2016-12-12 2020-09-08 江苏诺泰澳赛诺生物制药股份有限公司 一种地加瑞克的合成方法
CN109748954B (zh) * 2017-11-06 2022-03-01 正大天晴药业集团股份有限公司 一种地加瑞克的纯化方法
CN107955061B (zh) * 2017-11-15 2021-07-30 连云港恒运药业有限公司 地加瑞克关键中间体的制备方法
CN109929007B (zh) * 2017-12-15 2023-07-28 连云港恒运药业有限公司 地加瑞克关键二肽中间体的制备方法
CN110330552B (zh) * 2019-08-14 2021-03-16 凯莱英生命科学技术(天津)有限公司 醋酸地加瑞克的合成方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
ES2052488T3 (es) 1991-04-25 1997-01-01 Romano Deghenghi Peptidos antagonistas de la hormona de liberacion de la hormona luteinizante.
DE69330107T3 (de) 1992-02-12 2004-12-30 Daikyo Gomu Seiko, Ltd. Medizinisches Gerät
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5977302A (en) 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8105292B2 (en) 2008-02-11 2012-01-31 Safety Syringes, Inc. Reconstitution means for safety device
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
DK2421887T3 (en) * 2009-04-24 2015-07-27 Polypeptide Laboratories As A process for the preparation of degarelix
CN105663059A (zh) 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
RS55457B1 (sr) 2010-10-27 2017-04-28 Ferring Bv Postupak za proizvodnju degareliksa i njegovih intermedijara
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CA2841751A1 (en) 2011-07-15 2013-01-24 Raymond E. Joseph Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
IL225687A (en) 2017-06-29
EP2632935B1 (en) 2016-09-21
DK2632935T3 (en) 2016-11-14
JO3243B1 (ar) 2018-03-08
PT2632935T (pt) 2016-11-02
HUE030184T2 (en) 2017-04-28
ES2606753T3 (es) 2017-03-27
CA2815270A1 (en) 2012-05-03
AU2011322618B2 (en) 2015-05-21
TWI515201B (zh) 2016-01-01
SA111320880B1 (ar) 2015-03-30
US20160145301A1 (en) 2016-05-26
WO2012055905A1 (en) 2012-05-03
RS55193B1 (sr) 2017-01-31
US20130281661A1 (en) 2013-10-24
RU2602042C2 (ru) 2016-11-10
EP2632935A1 (en) 2013-09-04
CN103180335A (zh) 2013-06-26
BR112013010360A2 (pt) 2016-08-02
IL225687A0 (en) 2013-06-27
KR20130127443A (ko) 2013-11-22
US9822146B2 (en) 2017-11-21
BR112013010360B1 (pt) 2023-03-21
ZA201302670B (en) 2015-12-23
SI2632935T1 (sl) 2017-01-31
LT2632935T (lt) 2016-10-25
MX2013004320A (es) 2013-12-02
US9090656B2 (en) 2015-07-28
PL2632935T3 (pl) 2017-01-31
JP6007187B2 (ja) 2016-10-12
EP2447276A1 (en) 2012-05-02
KR101904808B1 (ko) 2018-10-05
TW201305186A (zh) 2013-02-01
HRP20161315T1 (hr) 2016-12-02
JP2013540793A (ja) 2013-11-07
AU2011322618A1 (en) 2013-05-02
NZ609064A (en) 2015-01-30
CN103180335B (zh) 2016-04-06
RU2013118446A (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
MX2013004320A (es) Proceso para la fabricacion de degarelix y sus intermedios.
PE20160788A1 (es) Procesos para preparar inhibidores de jak y compuestos intermediarios relacionados
WO2010056378A3 (en) Extracellular matrix compositions for the treatment of cancer
NZ599306A (en) Process for the preparation of compounds useful as inhibitors of sglt2
NZ598277A (en) Process for preparing azabicyclic compounds
NZ595942A (en) Processes for the preparation of rivaroxaban and intermediates thereof
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX356028B (es) Compuesto adyuvante.
WO2014054058A3 (en) Novel compounds, their synthesis and their uses
MX2013000773A (es) Procedimiento de preparacion de derivados de amino-benzoil-benzofu rano.
MX358463B (es) Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa.
MX2014007549A (es) 2-oxo-1,3-dioxolan-4-carboxamidas, su preparacion y uso.
MX340573B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
TR201900128T4 (tr) Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller.
BR112014008473A2 (pt) processo para a redução da perda de amônia e odor de material orgânico ou resíduo para a atmosfera, solução de nitrato ácida e instalação para a redução da perda de amônia
NZ595591A (en) Processes for the preparation of morphinane and morphinone compounds
MX352607B (es) Proceso para la preparacion de benzoxaboroles.
WO2011103610A3 (de) Pflanzenschutzmittel
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
CR20110593A (es) [1,2,4] triazolo [4,3-b] piridazina como ligandos del receptor de andrógenos
SG194727A1 (en) Method for modification of organic molecules
NZ594419A (en) Process for purifying guar
AR073807A1 (es) Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
CA2682895A1 (en) Synthesis of amine boranes
GB2519486A (en) A method for preparing oxycodone

Legal Events

Date Code Title Description
FG Grant or registration